Trizepatide (Mounjaro)
Tirzepatide (Mounjaro) Trizepatide, marketed under the brand name Mounjaro, is a medication used for the treatment of type 2 diabetes. Approved by the U.S. Food and Drug Administration (FDA) in May 2022, Mounjaro is notable for its unique mechanism of action, as it is the first medication to simultaneously activate both the glucagon-like peptide-1 (GLP-1)…